Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why
1. PHIO stock soared 378.7% with high trading volume of 201.04 million. 2. Complete response achieved in 2 patients with 100% tumor clearance. 3. Phase 1b study shows no significant adverse events for PH-762. 4. Preclinical studies support PH-762's tumor growth inhibition and safety. 5. PH-762 enhances T cell response in tumor microenvironment.